RNS & Investor News

Appointment of Joint Broker

10 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, is pleased to announce the appointment of Hybridan LLP as joint broker with immediate effect.

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive		 www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson		 Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey		 Tel: 020 7469 0936
Hybridan LLP
Joint Broker		 Tel: 020 3713 4581
Claire Louise Noyce
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort		 Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.